ACP Journal Club. Darbepoetin decreased transfusions and fatigue, but increased adverse effects in patients with chronic kidney disease, diabetes, and anemia
- PMID: 20231563
- DOI: 10.7326/0003-4819-152-6-201003160-02009
ACP Journal Club. Darbepoetin decreased transfusions and fatigue, but increased adverse effects in patients with chronic kidney disease, diabetes, and anemia
Comment on
-
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.N Engl J Med. 2009 Nov 19;361(21):2019-32. doi: 10.1056/NEJMoa0907845. Epub 2009 Oct 30. N Engl J Med. 2009. PMID: 19880844 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources